Clinical trial NCT02254031: Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer
Official title: An Open Phase I Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously Once Per Week for Three Weeks in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer With Repeated Administration Courses in Patients With Clinical Benefit
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Breast Neoplasms
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-10-01
Enrollment: 8
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine


Eligibility criteria: Inclusion Criteria:

1. female patients aged 18 years or older
2. patients with breast cancer positive for CD44v6 in at least 50 % of the tumour cells
3. patients with local and / or regional recurrent disease or distant metastases who are refractory to anthracyclines and / or taxanes (unless contraindications to taxanes and / or anthracyclines) or not amenable to established treatments
4. measurable tumour deposits by one or more radiological techniques (MRI, CT)
5. life expectancy of at least 6 months
6. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2
7. patients must have given written informed consent (which must be consistent with International Conference of Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation)

Exclusion Criteria:

1. hypersensitivity to humanised or murine antibodies, immunoconjugates or the excipients of the trial drugs
2. known secondary malignancy requiring therapy
3. active infectious disease
4. brain metastases requiring therapy
5. neuropathy grade 2 or above
6. absolute neutrophil count less than 1,500/mm3
7. platelet count less than 100,000/mm3
8. bilirubin greater than 1.5 mg/dl (\> 26 μmol/L, système internationale (SI) unit equivalent)
9. aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than 3 times the upper limit of normal
10. serum creatinine greater than 1.5 mg/dl (\> 132 μmol/L, SI unit equivalent)
11. concomitant non-oncological diseases which are considered relevant for the evaluation of the safety of the trial drug
12. chemo- or immunotherapy within the past four weeks prior to treatment with the trial drug or during the trial (except for present trial drug)
13. radiotherapy to breast and thorax region within the past four weeks prior to treatment with the trial drug or during the trial
14. women who are sexually active and unwilling to use a medically acceptable method of contraception
15. pregnancy or lactation
16. treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
17. patients unable to comply with the protocol

Primary outcomes:
measure: Maximum tolerated dose (MTD)
timeFrame: up to 6 months
Secondary outcomes:
measure: Incidence of adverse events
timeFrame: up to 14 days after last drug administration
measure: Number of patients with clinically significant findings in laboratory examinations
timeFrame: up to 14 days after last drug administration
measure: Number of patients with clinically significant findings in vital signs
timeFrame: up to 14 days after last drug administration
measure: Number of patients with development of Human Anti-Human Antibody (HAHA)
timeFrame: up to 14 days after last drug administration
measure: Area under the serum concentration time curve from time zero to time point 168 hours (AUC0-168)
timeFrame: up to 168 hours
measure: Area under the serum concentration time curve from time zero to the time of the last quantifiable drug concentration (AUC0-tz)
timeFrame: up to 14 days after last drug administration
measure: Area under the serum concentration time curve from time point zero to infinity (AUC0-∞)
timeFrame: up to 14 days after last drug administration
measure: Maximum serum concentration (Cmax)
timeFrame: up to 14 days after last drug administration
measure: Time to reach maximum serum concentration (tmax)
timeFrame: up to 14 days after last drug administration
measure: Terminal elimination half-life (t1/2)
timeFrame: up to 14 days after last drug administration
measure: Mean residence time (MRT)
timeFrame: up to 14 days after last drug administration
measure: Total body clearance (CL)
timeFrame: up to 14 days after last drug administration
measure: Volume of distribution at steady state (Vss)
timeFrame: up to 14 days after last drug administration
measure: Volume of distribution during the terminal elimination phase (Vz)
timeFrame: up to 14 days after last drug administration
measure: Trough concentration at steady state (Cpre,ss)
timeFrame: up to 7 days after drug administration
measure: Minimum serum concentration during the dosing interval τ at steady state (Cmin,ss)
timeFrame: up to 7 days after drug administration
measure: Linearity index (LI)
timeFrame: up to 14 days after last drug administration
measure: Accumulation factor (RA)
timeFrame: up to 14 days after last drug administration
measure: Tumor response
timeFrame: up to 14 days after last drug administration
Other outcomes:
Locations:
Study officials:
References: